On the basis of previous evidence, up-regulation of MTDH frequently occurred in multiple cancers, such as melanoma, breast cancer, and prostate cancer and the behavior of MTDH overexpression was also related to poor clinical outcome [40]. Here, MTDH is linked to prostate carcinoma.